ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded.
Clinical trials are the pathway to better treatments, better outcomes, and a future without cancer. We, as investigators, need to believe in them, and be willing to offer them to all patients who are eligible.
A trial of aqueous lidocaine to manage painful intercourse for breast cancer survivors was a small study with a great magnitude of benefit. Do we need to wait for more data, or can we start applying these findings for our patients today?
Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for their work, and to implement new findings for our patients.
A journal that aims to be the voice of global oncology has to publish work relating not only to differences in cancer biology due to risk factors, pathogenesis, and pharmacology, but also disparities arising from social, cultural, economic, and political resource-constraining issues.
More than 100 oncology practices have signed up to participate in ASCO's big data initiative. "We need good data, and lots of it, if we’re to draw meaningful conclusions that can improve patient care," writes CancerLinQ CEO Kevin Fitzpatrick.
I applaud the Foundation for Women’s Cancers for highlighting the importance of trials, and join them in their push for more trial options for not only my own patients, but for all patients with cancer.
The program is now available for this year's Research Community Forum Annual Meeting. Dr. Richard L. Schilsky invites you to join this unique event on September 24-25 in Alexandria, VA.
At the Plenary Session of this year’s ASCO Annual Meeting, the results of a longitudinal trial begun in 2007 showed me that patient engagement is much more important that I had imagined.
We’re making progress in better understanding, and communicating, the many issues surrounding adverse events, although not as fast as we’d like. In the long run, our patients will benefit from all of these initiatives.
The advent of rapid and relatively affordable high-throughput molecular analyses has permitted the development of a bewildering next generation of new cancer diagnostic tests that are being introduced into clinical care using our grandparents’ regulatory structure.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement